What we do Zenith Drugs Ltd manufactures and trades high-quality, affordable pharmaceutical formulations including ORS Powder, liquid orals, ointments, externals, and capsules. |
Founded in 2,000 |
Market share Well-established player in domestic pharmaceutical formulations with emerging export presence, particularly in Liberia. |
Problem solved Provides cost-effective medicines addressing essential healthcare needs, including hydration and topical treatments. |
Top clients or who we serve Serves domestic pharmaceutical retailers and healthcare providers with plans to expand exports to Liberia; primarily B2B. |
Key management Sandeep Bhardwaj (Managing Director), Bhupesh Soni (Director), Ajay Singh Dassundi (Executive Director). |
Our journey and innovations Started in 2001, shifted to GMP compliance in 2004, expanded product lines between 2007-2019, recently entered tablet manufacturing and direct export markets. |
Where we operate Mainly India with developing export operations in Liberia. |
Top products or what we offer ORS Powder, liquid orals, ointments, liquid externals, capsules, and tablets (new segment). |
Top brands BVM's Oral Rehydration Salts B.P. 27.9g (export focus). |
Raw materials needed Pharmaceutical raw ingredients for formulations and manufacturing chemicals. |
Raw materials supplier Not specified. |
Recurring vs cyclical contribution Revenue is primarily recurring through product sales in domestic and export markets. |
Our industry position Established in domestic pharma sector with GMP & WHO certifications; growing export footprint. |
Financial highlights FY 2024-25 revenue of Rs. 133.32 Cr with net profit Rs. 7.16 Cr; IPO raised Rs. 40.68 Cr in 2024. |
Geographical revenue split Domestic: Rs. 132.98 Cr; Export: Rs. 0.34 Cr (FY 2024-25). |
Order book - |
Whats driving growth Expansion into tablet manufacturing, new manufacturing facility, direct exports to Liberia, and diversified product portfolio. |
Our future plans Set up tablet manufacturing infrastructure; expand exports; increase production capacity with new Indore plant. |
Our green promise - |
Our people and values Committed to compliance, ethics, and safety; fostering a motivated workforce with transparent governance. |
Key challenges ahead Competition, regulatory compliance, expanding export footprint, and maintaining quality during growth. |
Interesting facts Converted from private to public limited company in 2023; WHO GMP certified facility; completed IPO in 2024. |
Risks and strategy Mitigating operational and market risks via certified quality practices, board oversight, and diversified product lines. |
